This is the authors' abstract. We don't add key points for this paper.
Background and Importance In Italy, patient (pt) access to oncological drugs is provided by the NHS, following authorisation by the European Medicines Agency (EMA) and negotiation with the Italian Medicines Agency (AIFA) for specific indications. Regulatory delays and the need for rapid access to innovative drugs, have prompted the utilisation of atypical drug access pathways. Atypical drug access pathways are expected to be increasingly used in the context of a Precision Oncology. Aim and Objectives The aim is to evaluate the distribution of drug types. Material and Methods We explored trends in atypical drug access at the Oncology Section of the Verona University and Hospital Trust, by examining Oncology and Pharmacy databases and regional registries of rare diseases and reviewing AIFA registry records. Data on atypical drug access were also correlated with the use of NGS-based molecular profiling. Results Between January 2016 and December 2021, a total of 355 atypical drug access requests for the treatment of cancer pts were recorded, with a peak in 2017. The two most common atypical access schemes were compassionate (including named patient and early access programmes, 61%) and off-label (21%) use. The latter steadily increased over time (from 8% in 2017 to 39% in 2021). Overall, the type of drugs requested were almost equally distributed between classical cytotoxic agents (CHT, 36%), immuno-oncology drugs (IO, 29%) and molecularly targeted agents (TT, 35%). Temporal trends in the usage of different classes of drugs are shown in table 1. Interestingly, TT requests decreased between 2016 and 2018 and stabilised at approximately 50% of total requests since 2019. Among 2019 and 2021, atypical drug access requests triggered by NGS-based extended molecular profiling significantly increased from 2.8% to 23.1% (p=0.0007). Conclusion and Relevance A trend towards increased off-label use of TT was identified, especially from 2019. Since 2019, NGS-informed requests have significantly increased to constitute almost 1/4 of all atypical drug access requests, clearly identifying a trend towards implementation of Precision Oncology in clinical practice. References and/or Acknowledgements Conflict of Interest No conflict of interest.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
FM Atsina (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: